Compare Alphabet Inc Class A (GOOGL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs State Street SPDR S&P Biotech ETF — how do they compare? Alphabet Inc Class A trades at $351.66 (market cap $4.24T), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: Alphabet Inc Class A is far larger — about 419.4× State Street SPDR S&P Biotech ETF's market cap, and Alphabet Inc Class A pays a 0.25% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GOOGL | XBI | |
|---|---|---|
Market Cap | $4.24T | $10.11B |
Volume | 23,392,850 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $402.62 | $169.55 |
52-Week Low | $236.59 | $104.99 |
Typical Hold Time | 85 Days | 38 Days |
Enterprise Value | $4.13T | — |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $351.66, up 0.33% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 86.75% analyst buy rating support positive sentiment, while YouTube's subscription price increase and AI partnerships with Anthropic and Intel highlight growth initiatives.
GOOGL presents a compelling investment case with 72 buy ratings and a $431.83 consensus price target offering 23% upside. Strong cash flow generation ($164.7B operating cash flow in 2025) and AI leadership position the stock for continued growth, though antitrust scrutiny and market volatility remain key risks requiring monitoring.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
